Segall Bryant Hamill buys $54.7 Million stake in Hologic (HOLX)

Hologic (HOLX) : Segall Bryant Hamill scooped up 148,387 additional shares in Hologic during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 12, 2016. The investment management firm now holds a total of 1,620,072 shares of Hologic which is valued at $54.7 Million.Hologic makes up approximately 1.37% of Segall Bryant Hamill’s portfolio.

Other Hedge Funds, Including , Massachusetts Financial Services Co boosted its stake in HOLX in the latest quarter, The investment management firm added 149,435 additional shares and now holds a total of 1,962,069 shares of Hologic which is valued at $66.2 Million. Hologic makes up approx 0.03% of Massachusetts Financial Services Co’s portfolio.Gsa Capital Partners Llp boosted its stake in HOLX in the latest quarter, The investment management firm added 33,286 additional shares and now holds a total of 84,762 shares of Hologic which is valued at $2.9 Million. Hologic makes up approx 0.18% of Gsa Capital Partners Llp’s portfolio.Finemark National Bank Trust reduced its stake in HOLX by selling 8,000 shares or 61.35% in the most recent quarter. The Hedge Fund company now holds 5,040 shares of HOLX which is valued at $170,100. Hologic makes up approx 0.02% of Finemark National Bank Trust’s portfolio.Washington Trust Co boosted its stake in HOLX in the latest quarter, The investment management firm added 25,550 additional shares and now holds a total of 550,846 shares of Hologic which is valued at $18.6 Million. Hologic makes up approx 1.24% of Washington Trust Co’s portfolio. Scout Investments added HOLX to its portfolio by purchasing 417,182 company shares during the most recent quarter which is valued at $14.1 Million. Hologic makes up approx 0.38% of Scout Investments’s portfolio.

Hologic opened for trading at $33.32 and hit $33.75 on the upside on Friday, eventually ending the session at $33.34, with a gain of 0.18% or 0.06 points. The heightened volatility saw the trading volume jump to 22,47,779 shares. Company has a market cap of $9,296,192 M.

On the company’s financial health, Hologic reported $0.47 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $0.46. The company had revenue of $693.30 million for the quarter, compared to analysts expectations of $687.43 million. The company’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.41 EPS.

Many Wall Street Analysts have commented on Hologic. Hologic was Downgraded by Needham to ” Hold” on Apr 28, 2016.

Hologic Inc. is a developer manufacturer and supplier of diagnostics products medical imaging systems and surgical products. The Company’s business units are focused on diagnostics breast health GYN surgical and skeletal health. The Company’s diagnostics products include Aptima family of assays its ThinPrep system the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases chlamydia and gonorrhea certain high-risk strains of human papillomavirus (HPV) and Trichomonas vaginalis the parasite that causes trichomoniasis. The Company’s GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems an ultrasound-based osteoporosis assessment product and its Fluoroscan mini C-arm imaging products.

Leave a Reply

Hologic - Is it time to Sell?

Top Brokerage Firms are advising their investors on Hologic. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.